USANA Health Sciences, Inc. announced its financial results for the fiscal fourth quarter and full year ended December 28, 2024. For Q4 2024, consolidated net sales were $214 million, a 3% decrease year-over-year, with diluted EPS at $0.23, down 74%. Adjusted diluted EPS was $0.64, a 26% decrease.
For the full fiscal year 2024, consolidated net sales reached $855 million, a 7% decrease from the prior year, and diluted EPS was $2.19, down 34%. Net earnings for the year were $42.0 million. The company ended the year with $182 million in cash and cash equivalents and $23 million of debt, following the Hiya acquisition.
USANA introduced its fiscal year 2025 outlook, projecting consolidated net sales between $920 million and $1.0 billion. Diluted EPS is expected to range from $1.50 to $2.20, with adjusted diluted EPS between $2.35 and $3.00. This outlook includes the impact of the Hiya acquisition and reflects strategic initiatives to drive customer growth and product innovation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.